T. Rowe Price (IMCR) lists 3,041,904 ADRs, a 6.0% stake in Immunocore
Rhea-AI Filing Summary
T. Rowe Price Investment Management, Inc. amended a Schedule 13G to report beneficial ownership of 3,041,904 ADRs of IMMUNOCORE HOLDINGS PLC as of 02/28/2026, representing 6.0% of the class. The filing lists sole voting and dispositive power over 3,041,904 ADRs.
The filing includes a signature dated 03/06/2026 and a statement denying beneficial ownership. No transaction price, purchase/sale direction, or cash‑flow details are provided in the excerpt.
Positive
- None.
Negative
- None.
Insights
T. Rowe Price reports a 6.0% ADR stake with sole voting and dispositive power.
The filing shows 3,041,904 ADRs and both sole voting and dispositive control listed, indicating the firm holds voting authority on these shares as of 02/28/2026. The statement denying beneficial ownership is a standard disclosure often tied to fund/account structures.
Impact is neutral: the holding size is disclosed but the excerpt does not show acquisitions, dispositions, or intent; subsequent filings would be needed to assess trading activity or strategy.
AI-generated analysis. How Rhea-AI works. Not financial advice.